You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

HOME
HIV-HBV Coinfection
Hepatitis C
HIV and AIDS
Hepatitis B
HIV-HCV Coinfection
HIV and AIDS Articles on:
  HIV-HBV Coinfection Main Section
 
Hepatitis B Main Section
 
HIV and AIDS Main Section
HOME PAGE

Thai Study Confirms Efficacy of Tenofovir (Viread) Regimens for HIV-HBV Coinfected Patients

By Liz Highleyman

Due to overlapping transmission routes, many people with HIV have also been exposed to hepatitis B virus (HBV). As the number of people infected with HIV increases in areas where HBV is endemic, such as southeast Asia, HIV-HBV coinfection is a growing concern that can complicate treatment for both disease.

Several approved and experimental anti-HBV drugs -- including tenofovir (Viread; also in the Truvada and Atripla coformulations), lamivudine (3TC; Epivir), emtricitabine (Emtriva), and, as recently reported, entecavir (Baraclude) -- are also active against HIV. Using such agents alone can lead to both viruses developing resistance.

Current HIV treatment guidelines recommend that HIV-HBV coinfected individuals who require therapy for chronic hepatitis B should receive a full HAART regimen containing dually active NRTIs.

As reported in the October 2008 issue of Hepatology, Gail Matthews and colleagues conducted a prospective clinical trial to compare anti-HBV monotherapy using lamivudine or tenofovir versus combination therapy with lamivudine plus tenofovir in HIV-HBV coinfected individuals in Thailand. A total of 36 coinfected patients initiating combination antiretroviral therapy for the first time were randomly assigned to receive either lamivudine, tenofovir, or both as anti-HBV agents within a HAART regimen.

Results

At week 48, the median HBV DNA reductions from baseline were 4.07 log10 copies/mL in the lamivudine arm, 4.57 log10 copies/mL in the tenofovir arm, and 4.73 log10 copies/mL in the lamivudine + tenofovir arm (P = 0.70).

In an intent-to-treat analysis, HBV DNA viral load was suppressed to < 3 log10 copies/mL in 46% of patients in the lamivudine arm, 92% in the tenofovir arm, and 91% in the lamivudine + tenofovir arm (P = 0.013).

HBV resistant mutations were detected in 2 participants, both in the lamivudine arm.

Hepatitis B "e" antigen (HBeAg) loss was observed in 33% of HBeAg positive patients and 8% experienced hepatitis B surface antigen (HBsAg) loss.

Hepatic flares were observed in 25% of study participants.

Lamivudine monotherapy resulted in a greater proportion of subjects with HBV DNA > 3 log10 copies/mL at week 48 and in early resistance development, the study authors concluded.

"This study confirms current treatment guidelines that recommend a tenofovir-based regimen as the treatment of choice for HIV-HBV coinfection, but does not demonstrate any advantage of HBV combination therapy in this short-term setting," they wrote.

National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia; HIV-Netherlands Australia Thailand Red Cross AIDS Research Centre, Bangkok, Thailand; Alfred Hospital, Melbourne, Australia; Department of Medicine, Monash University, Melbourne, Australia; Chulalongkorn University, Bangkok, Thailand; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia; Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.

10/14/08

Reference
GV Matthews, A Avihingsanon, SR Lewin, and others. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 48(4): 1062-1069. October 2008. (Abstract).

 

 

 


FDA-approved Therapies for Chronic HBV Infection

Baraclude  (entecavir)
Epivir-HBV  (lamivudine; 3TC)
Intron A (interferon alfa-2b)

Hepsera (adefovir dipivoxil)
Pegasys (peginterferon alfa-2a)
Tyzeka    (telbivudine)

 

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir)
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)